Condition Directory

Diabetes clinical trials

Directory of U.S. ClinicalTrials.gov public records for Diabetes. Browse Diabetes recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced September 29, 2026 Report an issue

ClinicalTrials.gov public records Last synced Sep 29, 2026, 7:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

4541

Shown on this page

Current sort

How Diabetes studies are organized in the registry

Generic “diabetes” listings mix type 1, type 2, and gestational diabetes, so the subtype is the first thing to pin down — this directory also has a dedicated type 2 diabetes page. Device studies (continuous glucose monitors, insulin delivery systems) are a large slice of the portfolio and are easiest to find by querying the device term itself.

Terms that often appear in related listings

type 1 diabetes type 2 diabetes continuous glucose monitor gestational diabetes

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1–12 of 4,541 matching trials for Diabetes.

Live ClinicalTrials.gov results.

Active filters: "type 1 diabetes" Clear condition filters

Local aggregate panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search

Conditions: Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
Interventions: NOURISH Diet, Self-Selected Diet (Control); Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetes Mellitus, Hepatitis C, Chronic, Cardiovascular Diseases
Interventions: Epclusa; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gestational Diabetes Mellitus (GDM), Metabolic Syndrome
Interventions: Semaglutide (Wegovy) weekly injection; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease, Retinal Vein Occlusion
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 2 Years to 120 Years
Enrollment: 650 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity, Overweight and/or Obesity, Overweight
Interventions: PF-08653944, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 954 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 34
States / cities: Canoga Park, California • Escondido, California • Modesto, California + 26 more

Conditions: Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 2,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 80
States / cities: Anniston, Alabama • Birmingham, Alabama • Pelham, Alabama + 74 more

Conditions: Weight Gain, Overweight, Insulin Resistance, Obesity, Diabetes Mellitus, Type 2
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 1,759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1983
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Interventions: ALV-100, Placebo; Drug
Lead sponsor: Alveus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Miami, Florida • Columbus, Ohio • San Antonio, Texas

Conditions: Obesity (Disorder), Diabetes Type 2, Heart Disease, Hypertension, Cancer, High Cholesterol
Interventions: Nutrition Education and Food Delivery, Physical Activity Comparator; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Type 2 Diabetes, Type 2 Diabetes (T2DM)
Interventions: Eroxon®, tadalafil; Device · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Nephrotic Syndrome, Lipodystrophy, Metabolic Syndrome, Healthy Volunteer, Diabetes, Metabolic Associated Steatotic Liver Disease
Interventions: High carb then high fat breakfast, High fat then high carb breakfast; Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: Retatrutide, Semaglutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 38
States / cities: Birmingham, Alabama • Escondido, California • Long Beach, California + 34 more

About this Diabetes clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Diabetes as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Diabetes.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Diabetes clinical trials

How Diabetes studies are organized in the registry

Filter and sort this condition

Live official records

Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes

People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus

National Eye Institute Biorepository for Retinal Diseases

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Cross-Sectional and Longitudinal Studies of "Pre-Diabetes" in the Pima Indians

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

Healthy Living Anson Study

PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)

Effects of Meal Macronutrients on Postprandial Lipids

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

About this Diabetes clinical trials directory page